ChemPartner PharmaTech Co (300149) Fair Value & Analysis
Healthcare · CN · Market cap 3.8B CNY
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 34 days ago
Share price +18.7% over the past month.
A solid business, but screening 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.19). The favourable scenario is already priced in.
- The model range is unusually wide (¥0.4400 to ¥1.19). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range ¥3.79 – ¥20.55 · fair‑value band ¥0.4400 – ¥1.19 · the ¥10.42 price screens above the ¥1.03 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
ChemPartner PharmaTech Co (300149) currently trades at ¥10.42, while our model-based Fair Value estimate is ¥1.03, implying the stock looks roughly 90.1% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, ChemPartner PharmaTech Co generated revenue of 1.1B CNY at a net margin of -1.0%. Revenue grew 2.1% year over year. It earns a return on equity of -0.9%. Net debt stands at 613M CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥0.4400 (bear case) to ¥1.19 (bull case); at ¥10.42, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 37% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -90%, 300149 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥3.94) versus Dividend Discount (¥0.0900). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business.
Full company description
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehensive chemical drug research and development and biological drug services for large and medium-sized pharmaceutical companies, biotechnology companies, and scientific research institutions. The company was formerly known as Quantum Hi-Tech (China) Biological Co., Ltd. and changed its name to ChemPartner PharmaTech Co.,Ltd. in September 2020. ChemPartner PharmaTech Co.,Ltd. was founded in 2000 and is headquartered in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ChemPartner PharmaTech Co reported revenue of ¥1.1B in FY2025 versus ¥1.7B in FY2021, a compound −9.5%/yr. Reported net income was ¥13.4M in FY2025.
300149 screens 90% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare ChemPartner PharmaTech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ChemPartner PharmaTech Co (300149) overvalued or undervalued?
What is the fair value of 300149?
What is the quality score of 300149?
What is the revenue of ChemPartner PharmaTech Co (300149)?
What is the net profit margin of 300149?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ChemPartner PharmaTech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.